Number of employees
5
Annual revenue
$650000
Description
VIRAPUR is dedicated to ensuring you have full control of your personal information. We provide opt-out choices for having information passed on for marketing, advertising or promotional purposes. You may choose to receive the VIRAPUR newsletter, promotional materials, or information regarding our services. Furthermore, you may choose not to be included in our mailing list, and you may opt-out from receiving communication from us or affiliated third parties at a later date.
Since the company's inception, VIRAPUR has worked with many companies, government agencies and academic institutions to provide the highest quality viral produdcts and services along with exceptional customer service to further the development of many life-saving viral and vaccine products. We are committed to serving the industry; no virus is too esoteric and no project is too small.
We provide services for preclinical testing labs, including isolating and titrating virus from animal tissues and upper respiratory swabs and washes.
VIRAPUR serves the research, diagnostic and vaccine communities, providing specialized viral reagents including live virus preparations and quantitated viral nucleic acids. We perform antiviral testing of small molecules against virus panels. We also assist in viral clearance process development studies. We specialize in upper respiratory viruses, especially influenzas, RSV, CMV as well as adenovirus, herpes viruses, phage and many other biosafety level 2 and 3 agents. We invented the original adenovirus purification ViraKits™ in 2000 and the original AAV purification ViraKit™ line in 2004.
Marylou Gibson trained in adenovirology at the University of Illinois, with post-doctoral training in the herpesviruses at the University of Michigan and University of Chicago. Her many years of experience in the biotech industry took her from developing veterinary and human herpesvirus vaccines to Bristol-Myers Squibb then Immunex/Amgen where she was on the team that developed the cell line secreting the drug Enbrel. She was instrumental in the startup of UC San Diego's GeneTherapy Clinical Manufacturing program which later became Molecular Medicine Bioservices/SAFC Pharma.